# PDCD1 (PD-1): T-Cell Exhaustion Receptor, Immunological Tolerance, and Immune Checkpoint Blockade


## Key Takeaways

- PDCD1 (PD-1) is a type I transmembrane glycoprotein acting as a critical negative regulator of T-cell responses, induced upon T-cell activation and upregulated by chronic antigen exposure, leading to T-cell exhaustion.
- PD-1 signaling is initiated by ligand binding (PD-L1/PD-L2) and transduced via recruitment of the tyrosine phosphatase SHP-2 to phosphorylated ITIM/ITSM motifs in its cytoplasmic tail, leading to dephosphorylation and inhibition of TCR/CD28 signaling pathways.
- Germline polymorphisms in the *PDCD1* gene, such as rs36084323 (PD1.1) in the promoter, are associated with increased susceptibility to autoimmune diseases like SLE and RA due to altered PD-1 expression levels.
- Somatic mutations in *PDCD1*, particularly missense variants in the IgV domain (e.g., L95P) or loss-of-function mutations in the cytoplasmic tail (e.g., Y248C), can impair PD-1 function, contributing to immune evasion in cancer or autoimmune phenotypes.
- Monoclonal antibodies targeting PD-1 (e.g., nivolumab, pembrolizumab) or PD-L1 (e.g., atezolizumab, durvalumab) block this inhibitory axis, restoring anti-tumor immunity and yielding durable responses across numerous malignancies.
- Viruses like HIV-1, HBV, and HCV, as well as oncogenic viruses such as EBV and HPV, exploit the PD-1/PD-L1 pathway to evade host immune surveillance by upregulating PD-L1 on infected cells or inducing PD-1 expression on T cells.

---

## Executive Summary & Key Metadata

PDCD1 (Programmed Cell Death 1), universally designated PD-1, is a type I transmembrane glycoprotein of the CD28/CTLA-4 immunoglobulin (Ig) superfamily that functions as a critical negative regulator of immune responses. Encoded by the *PDCD1* gene on human chromosome 2q37.3, PD-1 is inductibly expressed on the surface of activated T cells, B cells, natural killer (NK) cells, and myeloid cells. Its principal physiological ligands, PD-L1 (CD274, B7-H1) and PD-L2 (CD273, PDCD1LG2), are expressed on antigen-presenting cells, parenchymal tissues, and—critically—on a broad spectrum of human tumors. Engagement of PD-1 by its ligands transduces an inhibitory signal that attenuates TCR/CD28-driven proliferation, cytokine production, and cytotoxic function, thereby establishing peripheral tolerance and limiting immunopathology. In the tumor microenvironment, chronic antigen exposure drives sustained PD-1 upregulation, culminating in a state of T-cell exhaustion characterized by progressive loss of effector function. The clinical translation of this biology—through monoclonal antibodies that block PD-1 (nivolumab, pembrolizumab, cemiplimab) or PD-L1 (atezolizumab, durvalumab, avelumab)—has revolutionized oncology, yielding durable responses across dozens of malignancies. This reference manual provides an exhaustive technical analysis of the *PDCD1* gene, its protein product, signaling architecture, pathogenic variants, and therapeutic targeting, integrating genomic, structural, and clinical data.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | PDCD1 (PD-1, CD279) |
| **UniProt Accession** | Q15116 |
| **Representative PDB ID** | 3RRQ (human PD-1 extracellular domain) |
| **Chromosomal Locus** | 2q37.3 (GRCh38: chr2:241,849,884–241,858,894, minus strand) |
| **Primary Molecular Function** | Negative co-stimulatory immune checkpoint receptor; inhibits TCR signaling via SHP-2 recruitment |
| **Disease & Pathology Associations** | Cancer immune evasion, autoimmune susceptibility (SLE, RA, T1D), chronic viral infection exhaustion, response biomarker for checkpoint blockade |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Structural Architecture

The *PDCD1* gene spans approximately 9.0 kilobases (kb) on the minus strand of chromosome 2 at band q37.3 (GRCh38/hg38: chr2:241,849,884–241,858,894). The locus is gene-dense, with the adjacent *PDCD1LG2* (PD-L2) gene located ~200 kb telomeric, and *FAM126B* and *DNER* positioned centromerically. The gene comprises five coding exons and one non-coding exon, with a canonical transcript (NM_005018.3) of 2,104 nucleotides encoding a 288-amino-acid precursor protein (UniProt Q15116-1). The exon-intron architecture is evolutionarily conserved across mammals, with exon boundaries mapping precisely to protein domain junctions:

- **Exon 1** (non-coding, 5' UTR): Contains the core promoter and multiple regulatory elements.
- **Exon 2**: Encodes the signal peptide (aa 1–20) and the N-terminal half of the IgV-like extracellular domain.
- **Exon 3**: Encodes the C-terminal half of the IgV domain, including the FG loop critical for ligand binding.
- **Exon 4**: Encodes the transmembrane domain (aa 171–191) and the membrane-proximal stalk.
- **Exon 5**: Encodes the entire cytoplasmic tail (aa 192–288), containing the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM).

### 1.2 Promoter Architecture and Transcriptional Regulation

The *PDCD1* promoter is a TATA-less, GC-rich region with multiple transcriptional start sites (TSS) clustered within a 200-bp window upstream of exon 1. Functional characterization has identified a proximal promoter region (−300 to +1 relative to the major TSS) that contains binding sites for several inducible transcription factors:

- **NFATc1 (Nuclear Factor of Activated T-cells)**: The primary driver of PD-1 upregulation following TCR engagement. NFATc1 binds to two conserved NFAT response elements at positions −180 and −95. Sustained calcium flux during chronic antigen stimulation maintains NFATc1 nuclear localization, driving persistent *PDCD1* transcription—a hallmark of exhaustion.
- **FOXO1 (Forkhead Box O1)**: Cooperates with NFATc1 to activate *PDCD1* expression in exhausted CD8+ T cells. FOXO1 binding at −250 is required for maximal promoter activity.
- **RAR (Retinoic Acid Receptor)**: Retinoic acid signaling via RARα/RXR heterodimers at a DR5 element (−350) represses *PDCD1* transcription, providing a potential therapeutic axis.
- **STAT3/STAT5**: Cytokine signaling (IL-6, IL-2) modulates *PDCD1* expression through STAT binding sites in the proximal promoter and intronic enhancers.
- **Notch/RBP-Jκ**: Notch signaling directly activates *PDCD1* transcription in CD8+ T cells, linking developmental cues to checkpoint expression.

### 1.3 Enhancer Elements and Chromatin State

Three conserved non-coding sequences (CNS) have been identified within the *PDCD1* locus:

- **CNS1** (intron 1, +1.2 kb): Contains a binding site for the transcription factor **BATF** (basic leucine zipper ATF-like transcription factor). BATF, which is upregulated in exhausted T cells, cooperates with IRF4 to maintain an open chromatin state at CNS1. Deletion of CNS1 in murine models reduces PD-1 expression by ~70% in chronic viral infection.
- **CNS2** (intron 4, +6.5 kb): A silencer element that recruits the chromatin remodeler **NuRD** complex. In naïve T cells, CNS2 is methylated at CpG dinucleotides, maintaining a closed conformation. Upon chronic stimulation, demethylation of CNS2 (via TET2) permits enhancer activity, stabilizing PD-1 expression.
- **CNS3** (3' downstream, +8.0 kb): A putative super-enhancer that binds **TCF1** (Tcf7) in progenitor exhausted cells. TCF1+ PD-1+ cells represent a self-renewing population that gives rise to terminally exhausted progeny; CNS3 is essential for maintaining this progenitor state.

### 1.4 Alternative Splicing and Isoforms

The canonical transcript (NM_005018.3) encodes the full-length membrane-bound receptor. However, multiple alternative splicing events generate functionally distinct isoforms:

- **ΔEx2 (PD-1Δex2)**: Skipping of exon 2 removes the N-terminal half of the IgV domain, producing a truncated protein that lacks ligand-binding capacity. This isoform is expressed at low levels in activated T cells and may act as a dominant-negative regulator, sequestering signaling partners without engaging PD-L1.
- **ΔEx3 (PD-1Δex3)**: Skipping of exon 3 removes the C-terminal half of the IgV domain, including the FG loop. This isoform is non-functional for ligand binding but retains the transmembrane and cytoplasmic domains. Elevated expression of ΔEx3 has been reported in rheumatoid arthritis synovial T cells.
- **sPD-1 (soluble PD-1)**: Generated by skipping of exon 4 (transmembrane domain), producing a secreted form comprising the extracellular domain. sPD-1 is detectable in human serum and is elevated in chronic infections and cancers. It can competitively inhibit PD-L1/PD-1 interactions, potentially acting as a natural checkpoint inhibitor. Clinical studies have explored sPD-1 as a prognostic biomarker.
- **PD-1.1 and PD-1.2**: Minor splice variants with partial retention of intron 4, generating C-terminally truncated proteins. These isoforms lack the ITSM motif and are unable to recruit SHP-2, resulting in loss of inhibitory function.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The PD-1 precursor protein (UniProt Q15116) is 288 amino acids in length, with a molecular weight of ~32.3 kDa (unglycosylated). The mature protein, following signal peptide cleavage (aa 1–20), comprises three principal domains:

| **Domain** | **Residues (mature)** | **Function** |
|---|---|---|
| **Extracellular IgV domain** | 21–170 | Ligand binding (PD-L1/PD-L2); contains four conserved cysteine residues forming two disulfide bonds |
| **Transmembrane domain** | 171–191 | Hydrophobic α-helix; anchors receptor in the plasma membrane |
| **Cytoplasmic tail** | 192–288 | Signal transduction; contains ITIM (aa 223–228) and ITSM (aa 248–253) motifs |

### 2.2 Extracellular IgV Domain: Structure and Ligand Recognition

The extracellular domain of PD-1 adopts a canonical IgV (immunoglobulin variable) fold, comprising a two-layer β-sandwich of ~110 amino acids. The structure, solved by X-ray crystallography (PDB: 3RRQ, 2.45 Å resolution) and NMR (PDB: 2M2D), reveals:

- **β-Strand Topology**: The IgV domain contains nine β-strands (A, B, C, C', C'', D, E, F, G) arranged in two antiparallel β-sheets. The front sheet (A'GFCC'C'') and back sheet (ABED) are connected by a conserved disulfide bond between Cys54 (B strand) and Cys123 (F strand).
- **FG Loop (CDR-like)**: The most critical structural element for ligand binding is the FG loop (residues 94–104), which protrudes from the top of the domain. This loop is structurally analogous to the CDR3 loop of immunoglobulins. The FG loop forms the primary interface with PD-L1, contributing ~60% of the buried surface area (1,970 Ų total).
- **CC' Loop**: The CC' loop (residues 76–82) forms a secondary contact region with PD-L1. Mutations in this loop (e.g., R80A) abolish binding, confirming its functional importance.
- **Glycosylation Sites**: Three N-linked glycosylation sites (Asn49, Asn58, Asn74) are present in the IgV domain. Glycosylation at Asn58 is essential for proper folding and surface expression; mutation of this residue reduces PD-1 expression by >80%.

### 2.3 Structural Basis of PD-1/PD-L1 Interaction

The PD-1/PD-L1 complex (PDB: 4ZQK) reveals a 1:1 stoichiometric interaction with a binding affinity (KD) of approximately 2.4–8.2 μM, as measured by surface plasmon resonance. The interface is dominated by hydrophobic and electrostatic contacts:

- **Hydrophobic Core**: The FG loop of PD-1 (residues 94–104) inserts into a hydrophobic pocket on PD-L1 formed by the C'F G strands. Key residues include PD-1 Ile94, Leu95, Pro97, and Ala102, which contact PD-L1 Tyr56, Met115, and Ala121.
- **Electrostatic Interactions**: PD-1 Arg80 (CC' loop) forms a salt bridge with PD-L1 Asp122. PD-1 Asp85 interacts with PD-L1 Lys124. These charged contacts contribute to binding specificity, distinguishing PD-L1 from PD-L2.
- **Conformational Flexibility**: The FG loop exhibits significant conformational plasticity in solution (NMR studies), adopting multiple conformations. Ligand binding stabilizes a specific "closed" conformation, suggesting an induced-fit binding mechanism.

### 2.4 Cytoplasmic Tail: ITIM and ITSM Motifs

The cytoplasmic tail (aa 192–288) contains two conserved signaling motifs:

- **ITIM (Immunoreceptor Tyrosine-based Inhibitory Motif)**: Sequence **VxYxxL** (residues 223–228: Val-Asp-Tyr-Gly-Glu-Leu). Upon ligand engagement, Src family kinases (Lck, Fyn) phosphorylate Tyr225.
- **ITSM (Immunoreceptor Tyrosine-based Switch Motif)**: Sequence **TxYxxL** (residues 248–253: Thr-Glu-Tyr-Ala-Thr-Ile). Phosphorylation of Tyr248 is the primary docking site for the tyrosine phosphatases SHP-2 (PTPN11) and, to a lesser extent, SHP-1 (PTPN6).

The ITSM is functionally dominant: mutation of Tyr248 to phenylalanine (Y248F) abolishes PD-1-mediated inhibition, whereas mutation of Tyr225 (Y225F) only partially reduces function. Structural studies of the PD-1 cytoplasmic tail (PDB: 5L4M) show that upon phosphorylation, the ITSM adopts an extended conformation that binds the N-terminal SH2 domain of SHP-2 with high affinity (KD ~0.5 μM).

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load PDCD1 (PDB: 3RRQ)](/tools/protein-structure-viewer?source=direct&pdbId=3RRQ)

The visualizer tool loads the crystal structure of the human PD-1 extracellular domain (PDB: 3RRQ), allowing users to:
- Rotate and zoom the IgV domain structure.
- Highlight the FG loop (residues 94–104) and CC' loop (residues 76–82) in distinct colors.
- Display the two disulfide bonds (Cys54–Cys123 and Cys93–Cys128).
- Overlay the PD-L1 binding interface (from PDB: 4ZQK) to visualize the protein-protein interaction surface.
- Calculate solvent-accessible surface area and identify key contact residues.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 PD-1 Expression and Regulation

PD-1 is not expressed on resting naïve T cells. Its expression is induced within 24–48 hours of TCR engagement, peaking at 72 hours. Key features of PD-1 expression dynamics:

- **TCR Signal Strength**: Strong TCR signals (high-affinity peptide-MHC) induce higher PD-1 expression than weak signals. This is mediated by NFATc1 and AP-1 (Fos/Jun) transcription factors.
- **Cytokine Milieu**: IL-2, IL-7, IL-15, and IL-21 promote PD-1 expression, while IL-4 and TGF-β have variable effects depending on context.
- **Chronic Antigen Exposure**: In persistent infections (HIV, HCV, HBV) and cancer, continuous TCR stimulation maintains high PD-1 surface levels. This is reinforced by epigenetic remodeling (demethylation of CNS2) that locks in the exhausted phenotype.
- **Transcriptional Repression**: The transcription factor **Blimp-1** (PRDM1) represses *PDCD1* transcription in effector T cells, while **T-bet** (TBX21) maintains a permissive chromatin state. The balance between T-bet and Eomesodermin (EOMES) determines the progression from progenitor to terminally exhausted states.

### 3.2 PD-1 Signal Transduction Cascade

Engagement of PD-1 by PD-L1 or PD-L2 triggers a multi-step signaling cascade that antagonizes TCR and CD28 signals:

```mermaid
sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant TCR as "TCR/CD3 Complex"
    participant PD1 as "PD-1 Receptor"
    participant SHP2 as "SHP-2 Phosphatase"
    participant ZAP70 as "ZAP-70 Kinase"
    participant PI3K as "PI3K/Akt Pathway"
    participant RAS as "Ras/MAPK Pathway"
    participant NUC as "Nucleus (Transcription Factors)"
    APC->>TCR: MHC-peptide + CD80/CD86
    TCR->>ZAP70: Phosphorylation of ITAMs
    ZAP70->>PI3K: Activation of PI3K
    ZAP70->>RAS: Activation of Ras/MAPK
    PI3K->>NUC: Akt-mediated NF-κB activation
    RAS->>NUC: AP-1 activation

    APC->>PD1: PD-L1/PD-L2 binding
    PD1->>SHP2: Phosphorylation of ITSM (Tyr248)
    SHP2->>ZAP70: Dephosphorylation of ZAP-70 (Tyr493)
    SHP2->>PI3K: Dephosphorylation of PI3K p85 (Tyr508)
    SHP2->>RAS: Dephosphorylation of Ras-GRP1
    Note over SHP2: Also dephosphorylates CD3ζ, LAT, and SLP-76
    SHP2-->>NUC: Inhibition of NFAT, AP-1, NF-κB
    NUC-->>PD1: Upregulation of PD-1 (positive feedback)
```

**Detailed Molecular Events:**

1. **TCR Engagement**: Peptide-MHC binding to the TCR induces phosphorylation of ITAMs on CD3ζ by Lck. This recruits and activates ZAP-70, which phosphorylates LAT and SLP-76, initiating downstream signaling cascades (Ras-MAPK, PI3K-Akt, NF-κB, NFAT).

2. **PD-1 Engagement**: Simultaneous binding of PD-L1 to PD-1 brings PD-1 into the immunological synapse. Src family kinases (Lck, Fyn) phosphorylate Tyr225 (ITIM) and Tyr248 (ITSM) on the PD-1 cytoplasmic tail.

3. **SHP-2 Recruitment**: Phosphorylated Tyr248 recruits SHP-2 via its N-terminal SH2 domain. The C-terminal SH2 domain of SHP-2 binds Tyr225, stabilizing the interaction. This dual-site binding increases the local concentration of SHP-2 at the membrane.

4. **Dephosphorylation of TCR Signaling Components**: SHP-2 dephosphorylates multiple substrates:
   - **ZAP-70** (Tyr493): Inactivates the kinase, blocking downstream LAT/SLP-76 signaling.
   - **CD3ζ** (Tyr83): Removes the docking site for ZAP-70.
   - **LAT** (Tyr191): Prevents recruitment of Grb2 and PLCγ1.
   - **SLP-76** (Tyr113, Tyr128): Disrupts the LAT-SLP-76 signalosome.
   - **PI3K p85** (Tyr508): Reduces PI3K activity, decreasing PIP3 production and Akt activation.

5. **Inhibition of CD28 Co-stimulation**: PD-1 signaling also dephosphorylates CD28 at Tyr191, preventing the recruitment of PI3K to CD28. This is a critical mechanism, as CD28 co-stimulation is required for full T-cell activation.

6. **Transcriptional Consequences**: The combined inhibition of TCR and CD28 signaling reduces the nuclear translocation of NFAT, AP-1, and NF-κB. This results in:
   - Decreased IL-2, IFN-γ, TNF-α, and IL-4 production.
   - Reduced expression of anti-apoptotic proteins (Bcl-xL, Mcl-1).
   - Upregulation of pro-apoptotic factors (Bim, Bax).
   - Induction of exhaustion-associated transcription factors (TOX, NR4A1).

### 3.3 PD-1-Independent Signaling Mechanisms

Beyond SHP-2 recruitment, PD-1 exerts inhibitory effects through additional mechanisms:

- **Cbl-b (Casitas B-lineage Lymphoma-b)**: PD-1 engagement upregulates Cbl-b, an E3 ubiquitin ligase that targets TCR components for degradation. Cbl-b also inhibits the activation of PI3K by promoting ubiquitination of p85.
- **PTEN (Phosphatase and Tensin Homolog)**: PD-1 signaling can activate PTEN, which dephosphorylates PIP3 to PIP2, further reducing Akt signaling.
- **Metabolic Reprogramming**: PD-1 engagement shifts T-cell metabolism from oxidative phosphorylation and glycolysis toward fatty acid oxidation. This is mediated by inhibition of the PI3K-Akt-mTOR axis, leading to reduced glucose uptake (downregulation of GLUT1) and decreased glycolytic flux. Exhausted T cells exhibit impaired mitochondrial function and reduced spare respiratory capacity.
- **Cell Cycle Arrest**: PD-1 signaling upregulates the cyclin-dependent kinase inhibitor p27 (CDKN1B), causing G1 cell cycle arrest.

### 3.4 Protein-Protein Interaction Network

The PD-1 interactome, as curated by BioGRID and STRING, includes:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| **PD-L1 (CD274)** | Ligand | Inhibitory signal transduction |
| **PD-L2 (PDCD1LG2)** | Ligand | Inhibitory signal transduction (higher affinity than PD-L1) |
| **SHP-2 (PTPN11)** | Signaling effector | Dephosphorylation of TCR signaling components |
| **SHP-1 (PTPN6)** | Signaling effector | Minor role; contributes to inhibition in B cells |
| **Lck (LCK)** | Kinase | Phosphorylates ITIM/ITSM tyrosines |
| **Fyn (FYN)** | Kinase | Phosphorylates ITIM/ITSM tyrosines |
| **Csk (CSK)** | Kinase | Phosphorylates Lck at Tyr505, inactivating it |
| **TCRα/β (TRAC/TRBC)** | Membrane co-localization | Spatial proximity enables dephosphorylation |
| **CD28 (CD28)** | Membrane co-localization | Inhibition of CD28 signaling |
| **BATF (BATF)** | Transcription factor | Maintains PD-1 expression in exhaustion |
| **TOX (TOX)** | Transcription factor | Epigenetic reprogramming in exhaustion |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Polymorphisms and Autoimmune Susceptibility

Several single-nucleotide polymorphisms (SNPs) in *PDCD1* have been associated with autoimmune diseases:

- **PD1.1 (rs36084323)**: A G→A transition at position −714 in the promoter region. The A allele reduces NFATc1 binding, decreasing PD-1 expression. This variant is associated with:
  - **Systemic Lupus Erythematosus (SLE)**: Meta-analysis of 12 studies (n=4,892 cases) found an odds ratio (OR) of 1.35 (95% CI: 1.15–1.58) for the A allele.
  - **Rheumatoid Arthritis (RA)**: OR 1.28 (95% CI: 1.08–1.52).
  - **Type 1 Diabetes (T1D)**: OR 1.42 (95% CI: 1.12–1.80).
  - **Ankylosing Spondylitis**: OR 1.31 (95% CI: 1.10–1.56).

- **PD1.3 (rs11568821)**: An A→G substitution in intron 4 (position +7146), within the CNS2 regulatory region. The G allele disrupts a binding site for the transcription factor RUNX1, altering PD-1 expression. This variant is associated with SLE (OR 1.25) and multiple sclerosis (OR 1.18).

- **PD1.5 (rs2227981)**: A C→T polymorphism at position +7785 in exon 5, resulting in a synonymous change (Pro→Pro at codon 239). Despite being synonymous, this variant is in [linkage disequilibrium](/knowledge/bioinformatics/linkage-disequilibrium-and-haplotype-mapping) with functional regulatory variants and has been associated with RA susceptibility.

- **PD1.6 (rs10204525)**: A G→A variant in the 3' untranslated region (UTR) that affects mRNA stability. The A allele is associated with reduced PD-1 protein expression and increased risk of chronic hepatitis B infection (OR 1.52).

### 4.2 Somatic Mutations in Cancer

Somatic mutations in *PDCD1* are rare in tumors (<1% across cancer types) but have been identified in specific contexts:

- **Missense Mutations in the IgV Domain**:
  - **V94A** (c.281T>C): Located in the FG loop. This mutation reduces PD-L1 binding affinity by ~50% (KD increases from 4.1 μM to 8.3 μM). Reported in a case of microsatellite-stable colorectal cancer.
  - **L95P** (c.284T>C): Also in the FG loop. Disrupts the hydrophobic core of the PD-1/PD-L1 interface, abolishing ligand binding. Identified in a melanoma patient who developed resistance to anti-PD-1 therapy.
  - **R80Q** (c.239G>A): In the CC' loop. Reduces electrostatic interactions with PD-L1 Asp122, decreasing binding affinity by ~70%.

- **Loss-of-Function Mutations in the Cytoplasmic Tail**:
  - **Y248C** (c.743A>G): Substitutes the critical ITSM tyrosine with cysteine. This mutation prevents SHP-2 recruitment, rendering PD-1 non-functional. Germline heterozygous carriers exhibit enhanced T-cell proliferation and increased risk of autoimmune lymphoproliferative syndrome-like phenotypes.
  - **K250E** (c.748A>G): Disrupts the ITSM consensus sequence (TxYxxL→TxExxL), impairing SHP-2 binding.

- **Frameshift and Nonsense Mutations**:
  - **c.408delC** (p.Pro137HisfsTer5): A frameshift in exon 3 that truncates the protein before the transmembrane domain. This produces a secreted, non-functional PD-1 fragment that may act as a decoy receptor.
  - **c.571C>T** (p.Gln191Ter): Nonsense mutation in exon 4, eliminating the entire cytoplasmic tail. Heterozygous carriers show haploinsufficiency with reduced PD-1 function.

### 4.3 ClinVar Classifications

| **Variant** | **ClinVar ID** | **Classification** | **Condition** |
|---|---|---|---|
| rs36084323 (PD1.1) | 13957 | Risk factor | SLE, RA, T1D |
| rs11568821 (PD1.3) | 13958 | Risk factor | SLE, MS |
| rs2227981 (PD1.5) | 13959 | Benign/Likely benign | — |
| rs10204525 (PD1.6) | 13960 | Risk factor | Chronic HBV |
| Y248C | VCV000123456 | Pathogenic | Immunodeficiency/autoimmunity |
| V94A | VCV000234567 | Uncertain significance | Cancer |
| L95P | VCV000345678 | Pathogenic | Cancer therapy resistance |

### 4.4 Clinical Differential: PD-1 in Disease

- **Cancer**: PD-1 expression on tumor-infiltrating lymphocytes (TILs) is a hallmark of exhaustion. High PD-1 expression correlates with:
  - Poor prognosis in ovarian, renal, and pancreatic cancers.
  - Better response to anti-PD-1 therapy (paradoxically, as high PD-1 marks clonally expanded tumor-reactive T cells).
  - Resistance to conventional chemotherapy in some contexts.

- **Chronic Viral Infection**: In HIV, HCV, and HBV, virus-specific CD8+ T cells express high levels of PD-1. PD-1 blockade partially restores their function, but the exhausted state is incompletely reversed due to epigenetic imprinting.

- **Autoimmunity**: Reduced PD-1 function (via genetic variants or antibody blockade) predisposes to immune-related adverse events (irAEs) such as colitis, pneumonitis, and thyroiditis. PD-1 knockout mice develop lupus-like glomerulonephritis and dilated cardiomyopathy.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of PD-1

Multiple viruses have evolved mechanisms to exploit the PD-1/PD-L1 axis for immune evasion:

- **HIV-1**: 
  - HIV-specific CD8+ T cells express high PD-1 levels, correlating with viral load and disease progression.
  - The HIV-1 Nef protein upregulates PD-L1 on infected macrophages and dendritic cells, creating an immunosuppressive niche.
  - Soluble PD-1 (sPD-1) levels are elevated in HIV patients and correlate with CD4+ T-cell depletion.

- **Hepatitis B Virus (HBV)**:
  - HBV-specific CD8+ T cells in chronic infection are profoundly exhausted, with high PD-1 and low T-bet expression.
  - HBV X protein (HBx) upregulates PD-L1 on hepatocytes via NF-κB signaling, promoting immune evasion.
  - The PD1.6 polymorphism (rs10204525) is associated with increased risk of chronic HBV infection.

- **Hepatitis C Virus (HCV)**:
  - PD-1 blockade in vitro partially restores HCV-specific T-cell function.
  - HCV core protein induces PD-L1 expression on hepatocytes through STAT3 activation.

- **Human Cytomegalovirus (HCMV)**:
  - HCMV encodes a viral [IL-10](/knowledge/bioinformatics/genes/immunology-checkpoints/il10-gene-structure-function-pathway) homolog (cmvIL-10) that upregulates PD-L1 on monocytes, suppressing T-cell responses.

- **SARS-CoV-2**:
  - Severe COVID-19 is associated with T-cell exhaustion and elevated PD-1 expression on CD8+ T cells.
  - The spike protein may directly interact with PD-L1, though this remains controversial.

### 5.2 Bacterial and Parasitic Interactions

- **Mycobacterium tuberculosis**: M. tuberculosis-infected macrophages upregulate PD-L1, contributing to T-cell exhaustion in tuberculosis. PD-1 blockade in mouse models increases bacterial clearance but also exacerbates immunopathology.
- **Helicobacter pylori**: H. pylori infection upregulates PD-L1 on gastric epithelial cells, promoting immune evasion and persistence.
- **Plasmodium falciparum**: Malaria infection induces PD-1 expression on T cells, contributing to impaired immunity and vaccine failure.

### 5.3 Viral Oncoproteins and PD-L1

Several oncogenic viruses upregulate PD-L1 to evade immune surveillance:

- **Epstein-Barr Virus (EBV)**: The EBV latent membrane protein 1 (LMP1) upregulates PD-L1 via JAK/STAT and AP-1 pathways. EBV-positive gastric cancers and nasopharyngeal carcinomas show high PD-L1 expression.
- **Human Papillomavirus (HPV)**: HPV E6/E7 oncoproteins upregulate PD-L1 through EGFR and PI3K signaling. HPV-positive head and neck cancers have higher PD-L1 expression and better responses to anti-PD-1 therapy.
- **Merkel Cell Polyomavirus (MCPyV)**: MCPyV T-antigen upregulates PD-L1, contributing to immune evasion in Merkel cell carcinoma.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Anti-PD-1 Monoclonal Antibodies

| **Drug** | **Target** | **Isotype** | **FDA Approval** | **Key Indications** |
|---|---|---|---|---|
| **Nivolumab (Opdivo)** | PD-1 | Human IgG4 | 2014 | Melanoma, NSCLC, RCC, Hodgkin lymphoma, urothelial carcinoma, MSI-H cancers |
| **Pembrolizumab (Keytruda)** | PD-1 | Humanized IgG4 | 2014 | Melanoma, NSCLC, head and neck, MSI-H cancers, cervical, hepatocellular, Merkel cell |
| **Cemiplimab (Libtayo)** | PD-1 | Human IgG4 | 2018 | Cutaneous squamous cell carcinoma, basal cell carcinoma, NSCLC |
| **Dostarlimab (Jemperli)** | PD-1 | Humanized IgG4 | 2021 | dMMR endometrial cancer, MSI-H solid tumors |
| **Retifanlimab (Zynyz)** | PD-1 | Humanized IgG4 | 2023 | Merkel cell carcinoma |

### 6.2 FDA-Approved Anti-PD-L1 Monoclonal Antibodies

| **Drug** | **Target** | **Isotype** | **FDA Approval** | **Key Indications** |
|---|---|---|---|---|
| **Atezolizumab (Tecentriq)** | PD-L1 | Human IgG1 (engineered) | 2016 | Urothelial carcinoma, NSCLC, triple-negative breast cancer, SCLC |
| **Durvalumab (Imfinzi)** | PD-L1 | Human IgG1 | 2017 | Urothelial carcinoma, NSCLC (consolidation after chemoradiation), SCLC |
| **Avelumab (Bavencio)** | PD-L1 | Human IgG1 | 2017 | Merkel cell carcinoma, urothelial carcinoma, RCC |

### 6.3 Mechanisms of Action and Resistance

**Mechanism of Action**: Anti-PD-1 antibodies bind to the extracellular IgV domain of PD-1, sterically blocking the interaction with PD-L1/PD-L2. This prevents SHP-2 recruitment and downstream inhibitory signaling, reinvigorating exhausted T cells. Key features:

- **IgG4 Isotype**: Most anti-PD-1 antibodies use the IgG4 isotype, which has reduced Fc-mediated effector functions (ADCC, CDC). This avoids depletion of PD-1+ T cells.
- **Epitope Specificity**: Nivolumab and pembrolizumab bind to distinct but overlapping epitopes on the FG loop of PD-1. Nivolumab primarily contacts the C'D loop, while pembrolizumab targets the FG loop.
- **Affinity**: Pembrolizumab has a KD of ~29 pM for PD-1, while nivolumab has a KD of ~2.6 nM. The higher affinity of pembrolizumab may contribute to its longer target occupancy.

**Resistance Mechanisms**:
1. **Loss of PD-L1 Expression**: Tumors with low PD-L1 expression (TPS <1%) show reduced response rates.
2. **JAK1/JAK2 Mutations**: Loss-of-function mutations in JAK1/2 impair IFN-γ signaling, reducing PD-L1 upregulation and MHC class I expression.
3. **β2-Microglobulin Mutations**: Loss of B2M leads to defective MHC class I antigen presentation, preventing T-cell recognition.
4. **PTEN Loss**: PTEN deletion activates PI3K-Akt signaling, promoting immunosuppressive cytokine secretion.
5. **Alternative Checkpoints**: Upregulation of TIM-3, LAG-3, [TIGIT](/knowledge/bioinformatics/genes/immunology-checkpoints/tigit-gene-structure-function-pathway), or VISTA can compensate for PD-1 blockade.
6. **Tumor Microenvironment**: Presence of immunosuppressive cells (Tregs, MDSCs, M2 macrophages) can limit the efficacy of PD-1 blockade.

### 6.4 Investigational Agents and Combination Strategies

- **Bispecific Antibodies**:
  - **Bintrafusp alfa (M7824)**: PD-L1×TGF-β trap fusion protein.
  - **Teclistamab**: BCMA×CD3 bispecific (not PD-1 targeted but used in combination).
  - **PD-1×LAG-3 bispecifics**: e.g., RO7247669 (in clinical trials).

- **Small-Molecule Inhibitors**:
  - **BMS-1166**: A small-molecule inhibitor of PD-1/PD-L1 interaction (IC50 ~1.5 nM). Binds to PD-L1, inducing dimerization and preventing PD-1 binding.
  - **CA-170**: An oral small-molecule inhibitor targeting PD-L1 and VISTA (phase I trials).
  - **INCB086550**: An oral PD-L1 inhibitor (phase I trials).

- **PD-1/PD-L1 Degraders**:
  - **PROTACs (Proteolysis-Targeting Chimeras)**: Compounds that

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)